Bharat Biotech is reducing the price of its malaria vaccine by 40% to EUR 5.50 per dose, starting in early 2027. Partnering with Gavi and UNICEF, the company aims to save immunization programs $50 million through 2029 while reaching more children. The move follows a significant $200 million manufacturing expansion to stabilize supply for high-risk regions in Africa.
Bharat Biotech International has announced a significant price reduction for its malaria vaccine, Mosqivac. Starting in early 2027, the cost per dose will drop by approximately 40%, reaching EUR 5.50. This decision comes as part of a broader agreement with Gavi, the Vaccine Alliance, and UNICEF, aimed at making the vaccine more affordable and accessible for countries with high infection rates.
This price cut is built on a foundation of increased manufacturing efficiency. Previously, the company and its partner, GlaxoSmithKline, invested a combined $200 million into building specialized manufacturing facilities and transferring the necessary technology. In the pharmaceutical sector, a transfer of technology is critical when the original developer cannot meet global demand alone. By utilizing Bharat Biotech's manufacturing scale, the partnership aims to lower the cost per unit, allowing global health organizations to stretch their limited budgets further.
The initiative is projected to save international child immunization programs roughly $50 million between 2027 and 2029. This financial relief is vital for the sustainability of public health projects in Africa, where demand for the vaccine has historically outpaced the available supply. To date, over 74 million doses have been sent to 25 African countries, highlighting the massive scale of the rollout.
For investors and observers of the sector, the key to this strategy is volume. The company’s goal is to help vaccinate 50 million children against malaria by 2030. However, meeting this target involves risks. The sustainability of this model depends on continuous financial backing from organizations like the International Finance Facility for Immunisation, as well as the successful, long-term operation of the newly built manufacturing lines. Any disruption in raw material supply or challenges in the complex distribution logistics across remote regions could impact these delivery targets.
Moving forward, the focus for the company will be on maintaining the promised production capacity. The market will monitor whether these infrastructure investments can consistently deliver the required volume to meet the 2030 goal without impacting quality or profit margins, as the company transitions into a high-volume, lower-price global supplier model.